AnaptysBio Stock Discussion

$AnaptysBio(ANAB.US)$
NEWS
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Positive
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence ...

$AnaptysBio(ANAB.US)$
NEWS
Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties

$AnaptysBio(ANAB.US)$  Go baby go...

$Travere Therapeutic(TVTX.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Insmed(INSM.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Jaguar Health(JAGX.US)$  Phas...

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$Hutchmed (China)(HCM.US)$  Phase 3
$Viracta Therapeutics(VIRX.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Marinus Pharmaceuticals(MRNS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3...

$AnaptysBio(ANAB.US)$ Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) HALT off at 8:30 AM est

Upgrades
• $Box Inc(BOX.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $34 (from $32)
• $CF Industries Holdings(CF.US)$: RBC Capital Upgrades to Outperform from Sector Perform - PT $135 (from $110)
• $New Gold(NGD.US)$: RBC Capital Upgrades to Outperform from Sector Perform - PT $1.25 (from $1)
• $Sensei Biotherapeutics(SNSE.US)$: Oppenheimer Upgrades to Outperform from Perform - PT $5
• $Senetas Corp Ltd(SEN.AU)$ : Tru...